Hims & Hers (HIMS) stock is on a tear, and some analysts think Wall Street still isn’t bullish enough.
Jefferies analyst Glen Santangelo just doubled his price target for the telehealth platform, raising it from $25 to $50 per share after its acquisition of European digital health firm ZAVA.
But even that aggressive target is already lagging behind reality: HIMS briefly touched $60 on Tuesday and currently trades around $59.
The stock is up 135% year-to-date, far outperforming most growth stocks and crushing the broader market.
As Investors Observer recently reported, 2025 is shaping up as a breakout year for Hims & Hers. Analyst Riyado Sofian believes the company could cross $1 billion in revenue this year from its weight-loss business alone.
That bullish call follows a strong first quarter, where HIMS reported $230 million in weight-loss revenue, largely driver by its popular telehealth subscription model and direct-to-consumer reach with younger, digitally native patients.
Some technical analysts say the chart looks just as strong as the fundamentals. Heisenberg and TrendSpider both highlighted setups pointing to a potential breakout toward new all-time highs.
"You’re not bullish enough on HIMS," added NightHawk Capital, arguing that the $150 million to $300 million ZAVA acquisition still isn’t fully priced in.
You're not bullish enough on $HIMS.
undefined NightHawk Capital (@NighthawkTradez) June 15, 2025
Grab a hard mint and get ready to rock and roll baby. 🚀 pic.twitter.com/MArWerVtdN
Growth keeps growing…
The momentum hasn’t let up in Q2.
Analysts at Hims House reported the company "just posted its strongest week of the quarter," citing rising new customer acquisition and robust sales across multiple segments.
Search trends for terms like “Hims weight” and “Hers weight” are also spiking, according to the firm’s lead analyst Jonathan Stern, indicating strong organic demand for its weight management offerings.
The subscription-heavy model gives Hims & Hers steady recurring revenue, while its personalized healthcare approach continues to appeal to millennials and Gen Z consumers looking for convenience.
But not every analyst is ready to call it a slam dunk.
Healthcare analyst Michael Cherny noted that with the FDA’s recent decision declaring the semaglutide shortage officially over, Hims & Hers can no longer rely on selling compounded versions of the blockbuster weight-loss drug.
“With that shift, Hims now needs to lean more heavily on broadening its weight management product line to sustain its current growth trajectory,” Cherny said.
Your email address will not be published. Required fields are markedmarked